Reasons to Retain Doximity Stock in Your Portfolio for Now
DOCS' AI expansion is opening new growth avenues, but rising AI costs and tight pharma budgets could temper near-term gains.
Doximity Q1 Earnings Call Highlights
Doximity NYSE: DOCS reported fiscal 2027 first-quarter revenue of $157 million, up 7% from a year earlier, as the company cited improving demand from pharmaceutical and hospital customers and increased engagement with its clinical artificial intelligence tools.
DOCS Q1 Earnings Miss on Higher AI Costs, Revenues Beat, FY27 View Up
Doximity raises fiscal 2027 revenue guidance as AI adoption and pharma demand fuel growth, even as higher AI investments pressure margins.
Sell Doximity Into The Major Rally Following Its Q1 Results
Doximity, Inc. surged over 180% pre-market after its Q1 FY27 print, despite only marginally beating on revenue and missing on earnings. Fiscal Q3 revenue guidance of $170.5M at the midpoint is about 13% above consensus, signaling a potential inflection in growth expectations. Recent growth had slowed to just 5% in Q4, so the new guidance represents a notable acceleration relative to prior quarters.
Doximity stock is reversing post-earnings rally: why that shouldn't surprise you
Doximity (DOCS) stock as much as doubled on Friday morning after the digital platform for health care professionals posted a solid Q1 sales beat and issued seemingly impressive full-year guidance. Still, a closer look under the hood suggests these explosive gains are built on a fragile foundation, and the company might just end up paring them back in the days ahead.
Here's Why Doximity Stock Is Flying Today
Shares of Doximity are rocking higher Friday. The reason?
Doximity's stock skyrockets 50% on medical AI excitement. Can the rally last?
While one analyst thinks Doximity has a compelling AI opportunity, another worries that the company could cannibalize its core business of medical networking.
'LinkedIn for Doctors' Stock Nearly Doubles After Earnings
Doximity Inc (NYSE:DOCS) stock is scaling Wall Street today, up 59% to trade at $32.80.
Shares of this digital medical platform were up more than 100% at one point. Here's what's driving it
Doximity had a solid first quarter and raised its full year revenue guidance. But AI search isn't baked into these forecasts, analysts believe, and it's bringing in 10 times the revenue it costs to run, the CEO revealed on the conference call.
Doximity Jumps On Earnings: Explaining The Outsized Stock Move (Rating Upgrade)
Doximity, Inc. is upgraded to buy as the narrative shifts from stagnation to credible reacceleration, driven by AI engagement and improved revenue guidance. Revenue grew 7% YoY to $156.6M, with FY27 guidance raised to $671–681M, while margins compressed due to intentional reinvestment in AI and sales. AI tools, especially Doximity Ask, are rapidly integrating into physician workflows, positioning DOCS for deeper engagement and future monetization opportunities.
Doximity, Inc. (DOCS) Q1 2027 Earnings Call Transcript
Doximity, Inc. (DOCS) Q1 2027 Earnings Call Transcript
Doximity (DOCS) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Doximity (DOCS) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
